AVO Advanced Oncotherapy

Hardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum

Hardman & Co Research
Hardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum

26-Feb-2020 / 15:40 GMT/BST

Hardman & Co Research: Confidence in LIGHT gaining momentum

Advanced Oncotherapy plc (AVO) is the topic of discussion when Dr Martin Hall joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up to date with the LIGHT system and tells us his overall conclusion from his report and the company as an investment case.

Please click on the link below to listen to the interview:

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall

22

 


 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

984199  26-Feb-2020 

fncls.ssp?fn=show_t_gif&application_id=984199&application_name=news&site_id=research_pool
EN
26/02/2020

Underlying

AVOAdvanced Oncotherapy

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Advanced Oncotherapy

Martin Hall
  • Martin Hall
SN. SMITH & NEPHEW ...
ETX E-THERAPEUTICS ... (+18)

Hardman & Co Insight: Survival of the UK life sciences sector

For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This is quite unusual for healthcare stocks. Apart from the general economic influences, which have made institutions more risk-averse, there was a common knowledge that several companies were in need of additional working capital; so, share prices were marked down in anticipation of equity raises. However, the small- and mid-cap life sciences sector has alway...

SN. SMITH & NEPHEW PLC
ETX E-THERAPEUTICS
AGY ALLERGY THERAPEUTICS PLC
AVO ADVANCED ONCOTHERAPY
YGEN YOURGENE HEALTH
ALNOV NOVACYT SAS
C4XD C4X DISCOVERY HOLDINGS
REDX REDX PHARMA
GDR GENEDRIVE
GSK GLAXOSMITHKLINE PLC
AZN ASTRAZENECA PLC
CTEC CONVATEC GROUP PLC
RENE RENEURON GROUP
0008964D INDIVIOR INC
IMCR IMMUNOCORE HOLDINGS ADS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
TRX TISSUE REGENIX GROUP PLC
06/25/24 June 25, 2024 1 EN
Mark Thomas ... (+2)
  • Mark Thomas
  • Martin Hall
AVO Advanced Oncoth...
RECI Real Estate Cre... ... (+9)

The Hardman & Co Monthly: June 2024

Feature article: Two worlds divided by a common language Summary Few people would deny that raising capital in 2023 and 2024 has been very challenging. The key components of the market, the “two worlds” of corporates and investors, are nowadays often far apart in how they assess value – pre-COVID, this was much less of an issue. This has resulted in frustration and inertia, which, on a sustained basis, can have a significant negative impact on companies and the economy. This issue needs urgen...

AVO ADVANCED ONCOTHERAPY
RECI REAL ESTATE CREDIT INVESTMENTS
VTAS VOLTA FINANCE (GBP)
STX SHIELD THERAPEUTICS
HAT H&T GROUP
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
A0MXLB NB PRIVATE EQUITY PARTNERS
DUKE DUKE ROYALTY
06/03/24 June 3, 2024 1 EN
Brian Moretta ... (+4)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall
  • Paul Mylchreest
ARBB Arbuthnot Banki...
AVO Advanced Oncoth... ... (+12)

The Hardman & Co Monthly: May 2024

Feature article: Is silver the cheapest asset on the planet? Silver is a precious metal, a monetary metal and an industrial metal with a surprisingly wide range of uses. It’s not that well understood by investors and tends to get overshadowed by gold – but, perhaps, not for much longer. We think that the provocative title of this article is justified by silver’s attractive fundamentals. The “official figures” from the Silver Institute estimate that the silver market has been in deficit for the...

ARBB ARBUTHNOT BANKING GROUP
AVO ADVANCED ONCOTHERAPY
CLIG CITY OF LONDON INVESTMENT GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
VTAS VOLTA FINANCE (GBP)
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
HAT H&T GROUP
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
A0MXLB NB PRIVATE EQUITY PARTNERS
DUKE DUKE ROYALTY
05/02/24 May 2, 2024 1 EN
Brian Moretta ... (+5)
  • Brian Moretta
  • Keith Hiscock
  • Mark Thomas
  • Martin Hall
  • Yingheng Chen
ARBB Arbuthnot Banki...
AVO Advanced Oncoth... ... (+9)

The Hardman & Co Monthly: April 2024

Feature article: Steady as she goes, but could be better: A review of investment company liquidity since 2016 Liquidity is the lifeblood of equity markets. The measurement of liquid asset availability to a market or company is a way of gauging a market’s health. This article builds on our previous work, which analysed the liquidity data for non-financial trading companies, by applying the same analytical techniques to the investment companies (IC) space. We analyse liquidity for ICs as a whol...

ARBB ARBUTHNOT BANKING GROUP
AVO ADVANCED ONCOTHERAPY
CLIG CITY OF LONDON INVESTMENT GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
VTAS VOLTA FINANCE (GBP)
HAT H&T GROUP
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
A0MXLB NB PRIVATE EQUITY PARTNERS
04/02/24 April 2, 2024 1 EN
Mark Thomas ... (+2)
  • Mark Thomas
  • Martin Hall
ARBB Arbuthnot Banki...
AVO Advanced Oncoth... ... (+8)

The Hardman & Co Monthly: March 2024

Feature article: Streamed content takes over…after the Great Correction of 2022 Streaming is a disruptive, content-led, subscription-based technology. Challenging all video distribution business models, it opens up global opportunities for a growing variety of content, including gaming and sport. The Great Correction of 2022 saw the share prices of streamers plunge after market leader Netflix reported slowing subscriber growth. The slowdown in growth of subscribers led investors to refocus on ...

ARBB ARBUTHNOT BANKING GROUP
AVO ADVANCED ONCOTHERAPY
RECI REAL ESTATE CREDIT INVESTMENTS
VTAS VOLTA FINANCE (GBP)
HAT H&T GROUP
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
A0MXLB NB PRIVATE EQUITY PARTNERS
03/01/24 March 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch